Outset Medical Inc

The stock remains in a Stage 2 advancing environment, supported by a clear Higher Highs & Higher Lows pattern and rising short‐term EMAs, making pullbacks into the 9/21/50 EMA zone structurally attractive; short‐term timing is favorable now, though the long‐term downtrend below the 200 DMA and moderate bearish divergences at resistance pose risks.

• ↑Strong Tableau adoption and Next Gen pipeline drive demand
• ↑Recurring revenue from consumables and services at $22.5 M (+11% YoY)
• ↓Q1 product revenue $18.6 M down 13% YoY, reflecting lumpiness in capital orders